The startup is the first gene editing company to price an IPO in more than two years, though it banked far less than most ...

In a victory for Robert F. Kennedy Jr.’s “MAHA” agenda, panelists narrowly recommended broader use of four peptides despite a ...

The new findings position Lilly to file an application for the highly anticipated medicine, but also leave some questions ...

Analysts expect new details on the lead-up to the deal “are likely to reignite” investor scrutiny that Vertex overpaid in ...

The clearance is GSK’s first for a lung cancer medicine and the latest step forward in a yearslong push by the British ...

To analysts, the drug’s apparent safety and effects on both triglyceride levels and pancreatitis cases should make it ...

While the possibility of levies on branded pharmaceuticals have had a limited impact on drugmaker revenues, tariffs of up to ...

A new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck ...

The startup has a broad global development program underway — and the support of more than 20 investment firms — for a ...

The study failure costs Agios a chance to one-up Novo Nordisk and represents yet another setback in a disease that’s ...

The lawsuit follows a cease-and-desist request and argues Lilly is using “deceptive” ads to claim its GLP-1 products are ...

The young venture firm, which has bet heavily on tech and biotech’s convergence, has now invested in 35 companies and ...